The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Young lung cancer: Psychosocial needs assessment.
 
Narjust Florez
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Janssen; Merck; Mirati Therapeutics; NeoGenomics Laboratories; Pfizer; Regeneron
Other Relationship - Medscape; MJH Life Sciences
 
Lauren Kiel
No Relationships to Disclose
 
Miki Horiguchi
No Relationships to Disclose
 
Rebekah Kaufman
No Relationships to Disclose
 
Danielle Haradon
No Relationships to Disclose
 
Michelle Sanchez
No Relationships to Disclose
 
Ruth Lederman
No Relationships to Disclose
 
Emma Voligny
No Relationships to Disclose
 
Tom Nguyen
No Relationships to Disclose
 
Stephanie McDonald
No Relationships to Disclose
 
Fatima Wilder
No Relationships to Disclose
 
Cristina Pozo-Kaderman
No Relationships to Disclose
 
Pasi A. Janne
Stock and Other Ownership Interests - Gatekeeper Pharmaceuticals; Loxo
Consulting or Advisory Role - Abbvie; Accutar Biotech; Allorion Therapeutics; Araxes Pharma; AstraZeneca; Bayer; Biocartis; Biocartis; Blueprint Medicines; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Duality Biologics; Eisai; Frontier Medicines; Hongyun Biotech; Ignyta; Lilly; LOXO; Merrimack; Merus; Mirati Therapeutics; Monte Rosa Therapeutics; Novartis; Nuvalent, Inc.; Pfizer; Roche/Genentech; Sanofi; Scorpion Therapeutics; SFJ Pharmaceuticals Group; Silicon Therapeutics; Syndax; Takeda; Transcenta; Voronoi Health Analytics
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo (Inst); Lilly (Inst); Puma Biotechnology (Inst); Revolution Medicines (Inst); Takeda (Inst)
Patents, Royalties, Other Intellectual Property - I am a co-inventor on a DFCI owned patent on EGFR mutations licensed to Lab Corp. I receive post-marketing royalties from this invention
 
Bruce E. Johnson
Consulting or Advisory Role - Abdera Thereapeutics; AstraZeneca; BlueDot; Checkpoint Therapeutics; Daiichi Sankyo; G1 Therapeutics; Genentech; GlaxoSmithKline; Hummingbird Diagnostics; Jazz Pharmaceuticals; Merus NV; Novartis; Simcere
Patents, Royalties, Other Intellectual Property - Dana-Farber Cancer Institute
 
Ann H. Partridge
Research Funding - Novartis
Patents, Royalties, Other Intellectual Property - I receive small royalty payments for co-authoring the breast cancer survivorship section of UpToDate
 
Andrea Catherine Enzinger
Consulting or Advisory Role - Astellas Pharma (I); AstraZeneca (I); Daiichi Sankyo (I); Five Prime Therapeutics (I); Ioxo (I); ISTARI Oncology (I); Lilly (I); Merck (I); Novartis (I); Ono Pharmaceutical (I); Taiho Pharmaceutical (I); Takeda (I); Xencor (I); Zymeworks (I)
Research Funding - Medtronic